7.
Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B,
Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB.
13T
J Clin Oncol
13T
. 2011 Dec 1;29(34):4491-7.
8.
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM,
Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E,
Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M,
Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin
Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab
for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet. 2013 Sep 21;382(9897):1021-8.
9.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié
M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S,
Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial
investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with
HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet
Oncol. 2013 Jul;14(8):741-8
10.
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T,
Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus
intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-
positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label,
multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78.
11. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G,
Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S,
McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N,
Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang
I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor
Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant
Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol. 2015 Nov
23. pii: JCO621797. [Epub ahead of print]
12. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harker G, Masuda N, Neskovic
Konstantinovic ZB B, Petrakova K, Guerrero. Zotano AL L, Iannotti N, Rodriguez GI
I, Tassone P, von Minckwitz G, Ejlertsen B, Chia SKL K L, Mansi J, Barrios CH H,
5
